Smith & Nephew Report issue

Contributed to NME For profit Phase 1 Phase 2 Phase 3 Phase 4
Founded: Kingston upon Hull United Kingdom (1856)
Status: No NME R&D (1856)

Organization Overview

First Clinical Trial
2012
NCT01656889
First Marketed Drug
1965
collagenase clostridium histolyticum (xiaflex)
First NDA Approval
1997
becaplermin (regranex)
Last Known Activity
2021

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

SMITH AND NEPHEW | Smith and Nephew Biotherapeutics | Smith & Nephew Biotherapeutics; Chief Medical Officer | Smith & Nephew, Inc.

Active Ingredients

Marketed Drugs (5)

Key: Smith & Nephew (4) Acquired (1)

becaplermin (regranex) (1997 NDA)

collagenase clostridium histolyticum (xiaflex) (1965)

droperidol (innovar) (1988)

metoclopramide (reglan) (1987)

nitroglycerin (transderm-nitro) (1986)

Drugs in Phase 4 Trials (7)

Key: Smith & Nephew (1) Acquired (6)

aluminum hydroxide (Gaviscon) (1 trial)

bacitracin (polysporin) (4 trials)

collagenase clostridium histolyticum (xiaflex) (15 trials)

colloidal silver (1 trial)

lidocaine (xylocaine) (1 trial)

petrolatum, white (Vaseline) (3 trials)

ropivacaine (naropin) (2 trials)

Drugs in Phase 3 Trials (4)

Key: Smith & Nephew (0) Acquired (4)

autologous mesenchymal stem cells (2 trials)

cham (1 trial)

hp802-247 (9 trials)

remestemcel-l (2 trials)

Drugs in Phase 2 Trials (5)

Key: Smith & Nephew (0) Acquired (5)

castor oil (6 trials)

hp828-101 (2 trials)

hyaluronic acid (1 trial)

myroxylon balsamum (6 trials)

trypsin (6 trials)

Drugs in Phase 1 Trials (1)

Key: Smith & Nephew (0) Acquired (1)

human fibrin (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Diabetic Foot (Phase 4)

Foot Ulcer (Phase 4)

Leg Ulcer (Phase 3)

Pressure Ulcer (Phase 4)

Ulcer (Phase 4)

Varicose Ulcer (Phase 3)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 40
  • # of Trial APIs: 17